New Products In Brief
This article was originally published in The Gray Sheet
Boston Scientific’s next-gen defibrillators
You may also be interested in...
InspireMD plans stock offering to raise up to $46 million for stent system. Torax gets $30 mil. for GERD treatment. BioFire Diagnostics raises $25 mil. for FilmArray platform. More financings.
Boston Scientific’s ongoing effort to reorganize and recharge its product pipeline and reduce manufacturing costs will restore higher revenue growth over the next few years, executives said during a Nov. 19 day-long investor presentation.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.